FDA Clears ReAlta Life Science’s Phase II STAR Trial of RLS-0071 in Neonates with Hypoxic-Ischemic Encephalopathy

By
Justin.choi
-
0
15
ReAlta Life Sciences, Inc. announced FDA clearance of an investigational new drug application for a Phase II clinical trial of RLS-0071 in neonates with hypoxic-ischemic encephalopathy.
[ReAlta Life Sciences, Inc.]

Sorry, but the selected Zotpress account can't be found.

Graphical Abstract